dc-1

DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer, is an ADC cytotoxin, similar to the small groove-binding DNA alkylating agent CC-1065.

TCMDC-135051 is a potent and selective PfCLK3 protein kinase inhibitor demonstrating significant antiparasiticidal activity (EC50=320 nM) while exhibiting minimal off-target toxicity. It effectively hinders the transition from trophozoite to schizont, impairs transcription, and diminishes transmission to the mosquito vector.

ADC-13 ((5R,6S)-4-Nitrobenzyl 6-((R)-1-hydroxyethyl)-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate) is a p-nitrobenzyl ester β-lactam derivative, functioning as an intermediate in carbapenem antibiotic synthesis.

TCMDC-135051 TFA is a highly selective and potent inhibitor of protein kinase PfCLK3.

DC-159a, an 8-methoxy fluoroquinolone, possesses broad-spectrum antibacterial activity, with a particular efficacy against Gram-positive pathogens. The MIC90 values for DC-159a are 0.5 μg/mL against Streptococcus anginosus group, 4 μg/mL against Clostridium difficile, and 2 μg/mL against Bacteroides fragilis.

DC-174 is an orally active snake venom metalloproteinase (SVMP) inhibitor with broad-spectrum activity against various snake venom SVMPs. It binds directly to the active site of SVMP through a zinc-binding group, inhibiting its enzymatic activity and procoagulant toxicity. DC-174 significantly prolongs the survival time of mice under snake venom attack and is applicable for researching emergency treatment of snakebites.

CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4 nM, 2.4 nM, and 15.7 nM, respectively.

TCMDC-125457 can effectively induce calcium redistribution, but has little effect on inhibiting heme crystallization. When TCMDC-125457 is combined with artesunate, it can effectively treat tightly synchronized artemisinin-resistant ring-stage parasites.

TCMDC-125431 is a novel inhibitor of Plasmodium calcium kinetics with minimal inhibition of haemoglobin crystals.

TCMDC-136230 is a novel inhibitor of Plasmodium calcium kinetics with minimal inhibition of haemoglobin crystallisation.

TCMDC-135051 hydrochloride is a potent, highly selective, low off-target toxicity inhibitor of the protein kinase PfCLK3. TCMDC-135051 hydrochloride blocks the trophozoite to lysosome transition, disrupts transcription and inhibits transmission to mosquito vectors, exhibiting an antiparasitic effect with an EC50 value of 320 nM.

TCMDC-135051 TFA is a potent, highly selective, low off-target toxicity protein kinase PfCLK3 inhibitor that exhibits antiparasitic effects with an EC50 value of 320 nM. TCMDC-135051 TFA blocks the trophozoite to lytic transition, disrupts transcription and inhibits transmission to mosquito vectors.

DC-120 is an ATP competitive AKT kinase inhibitor that suppressed proliferation and induced apoptosis in liver cancer cells both in vitro and in vivo. DC120 blocked the phosphorylation of downstream molecules in the AKT signal pathway in dose- and time-dependent manners both in vitro and in vivo. DC120 inhibits AKT activity in vitro with an EC(50) of 153 nM. DC120 at 20 mg/kg/day inhibited the CNE2 xenograft tumor growth with a treated group/control group ratio of 38.1%, accompanied by increasing terminal deoxynucleotidyl transferasedUTP nick-end labeling-positive cells in the tumor sample.

BKIDC-1553, an orally active antiglycolytic agent and bumped kinase inhibitor-derived compound, has a predicted half-life of approximately 17 hours in humans. It inhibits CYP2C8 and Angiotensin Converting Enzyme, making it suitable for cancer research [1].

TCMDC-137332 is a compound exhibiting antimalarial activity against Plasmodium falciparum with an IC50 value of 7 nM, and can be utilized for malaria research [1].

Anti-Mouse CD205 Antibody (NLDC-145) is an inhibitor designed to target mouse CD205.

Rabacfosadine (GS-9219) is a novel dual pre-drug of the acyclic nucleotide phosphonate PMEG to tumor lymphocytes for the study of lymphoma.

Permethrin (NRDC-143) is a pyrethroid insecticide commonly used in the treatment of LICE INFESTATIONS and SCABIES.

Acid-C1-PEG5-Boc, a PEG-based PROTAC linker, is utilized in PROTAC synthesis.

DC1 is an ADC cytotoxin, similar to the small groove-binding DNA alkylating agent CC-1065. DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer. DC1Sme is a DC1 derivative with IC50 values of Ramos, Namalwa, HL60 / s

DC10SMe is a DNA alkylating agent that can be used in the synthesis of antibody-drug conjugates (ADC). The IC50 of DC10SMe for Ramos, Namalwa and HL60 / s cancer cells were 15 pM, 12 pM and 12 pM, respectively.

YL-5092 is a YTHDC1 inhibitor (IC50=7.4 nM, KD=29.6 nM) that suppresses cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and can be used in studies of acute myeloid leukemia (AML).

DDC18-8A is an amphiphilic dendritic polymer known for its potent antimicrobial and antibiofilm properties.

CDC14A/B-IN-1 (Compound 15) is an orally bioavailable inhibitor of CDC14A/B phosphatases, exhibiting inhibition constants (Ki) of 57.4 nM for CDC14A and 90.0 nM for CDC14B.